首页> 外文OA文献 >Up-regulation of A 2B adenosine receptor in A 2A adenosine receptor knockout mouse coronary artery.
【2h】

Up-regulation of A 2B adenosine receptor in A 2A adenosine receptor knockout mouse coronary artery.

机译:A 2A腺苷受体敲除小鼠冠状动脉中A 2B腺苷受体的上调。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In this study, we looked into possible compensatory changes of other adenosine receptors (ARs) in A(2A) genetic knockout mice (A2AKO) as well as the functional role of nitric oxide (NO) in A(2A) AR-mediated vasodilation. Gene expression of ARs from coronary arteries of A(2A) AR wild type mice (A2AWT) and A2AKO was studied using real-time PCR. Functional studies were carried out in isolated heart and isolated coronary artery preparations. A(2B) AR was found to be 4.5 fold higher in A2AKO than in A2AWT, while A(2A) AR expression was absent in A2AKO. There was no difference in A(1) and A(3) ARs between WT and KO animals. The concentration-relaxation curve for adenosine-5'-N-ethylcarboxamide (NECA, non-selective AR agonist) in isolated coronary arterial rings in A2AKO was shifted to the left when compared to A2AWT. The concentration-response curve for A(2B) selective agonist (BAY 60-6583) was also shifted to the left in A2AKO hearts. L-NAME, a non-specific NO synthase inhibitor, did not affect baseline coronary flow (CF) until the concentration reached 10 microM in A2AWT (76.32+/-11.35% from baseline, n=5). In A2AKO, the CF decreased significantly by L-NAME only at a higher concentration (100 microM, 93.32+/-5.8% from baseline, n=5). L-NMA (1 microM, n=4), another non-specific NO synthase inhibitor, also demonstrated similar results in decreasing CF (59.66+/-3.23% from baseline in A2AWT, while 81.76+/-8.91% in A2AKO). It was further demonstrated that the increase in CF by 100 microM NECA was significantly blunted with 10 microM L-NAME (377.08+/-25.23% to 305.41+/-30.73%, n=9) in A2AWT but not in A2AKO (153.66+/-22.7% to 143.88+/-36.65%, n=5). Similar results were also found using 50 nM of CGS-21680 instead of NECA in A2AWT (346+/-22.85 to 277+/-31.39, n=6). No change in CF to CGS-21680 was noted in A(2A)AKO. Our data demonstrate, for the first time, that coronary A(2B) AR was up-regulated in mice deficient in A(2A) AR. We also provide direct evidence supporting a role for NO in A(2A) AR-mediated coronary vasodilation. The data further support the role for A(2A) AR in the regulation of basal coronary tone through the release of NO.
机译:在这项研究中,我们调查了A(2A)基因敲除小鼠(A2AKO)中其他腺苷受体(ARs)的可能的补偿性变化以及一氧化氮(NO)在A(2A)AR介导的血管舒张中的功能。使用实时PCR研究了A(2A)AR野生型小鼠(A2AWT)和A2AKO的冠状动脉中AR的基因表达。在离体心脏和离体冠状动脉制剂中进行了功能研究。发现A(2B)AR在A2AKO中比在A2AWT中高4.5倍,而A(2A)AR在A2AKO中不存在。 WT和KO动物之间的A(1)和A(3)AR没有差异。与A2AWT相比,A2AKO中分离的冠状动脉环中腺苷5'-N-乙基羧酰胺(NECA,非选择性AR激动剂)的浓度松弛曲线向左移动。在A2AKO心脏中,A(2B)选择性激动剂(BAY 60-6583)的浓度反应曲线也向左移动。 L-NAME是一种非特异性NO合酶抑制剂,直到A2AWT中的浓度达到10 microM(相对于基线76.32 +/- 11.35%,n = 5)时才影响基线冠脉流量(CF)。在A2AKO中,仅在较高浓度(100 microM,相对于基线为93.32 +/- 5.8%,n = 5)下,L-NAME的CF显着降低。另一种非特异性NO合酶抑制剂L-NMA(1 microM,n = 4)也显示出相似的降低CF的结果(A2AWT中基线降低59.66 +/- 3.23%,A2AKO中81.76 +/- 8.91%)。进一步证明,在A2AWT中,用10 microM L-NAME(377.08 +/- 25.23%至305.41 +/- 30.73%,n = 9)显着抑制了CF通过100 microM NECA的增加,而在A2AKO(153.66+ /-22.7%至143.88 +/- 36.65%,n = 5)。在A2AWT中使用50 nM的CGS-21680代替NECA也发现了相似的结果(346 +/- 22.85至277 +/- 31.39,n = 6)。在A(2A)AKO中,未将CF更改为CGS-21680。我们的数据首次证明,在缺乏A(2A)AR的小鼠中冠状动脉A(2B)AR被上调。我们还提供直接证据支持NO在A(2A)AR介导的冠状血管舒张中的作用。数据进一步支持了A(2A)AR通过释放NO调节基础冠状动脉张力的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号